Artivion, Inc. (NYSE:AORT) Insider John E. Davis Sells 15,100 Shares

Artivion, Inc. (NYSE:AORT) insider John E. Davis sold 15,100 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $356,511.00. Following the transaction, the insider now directly owns 208,778 shares in the company, valued at approximately $4,929,248.58. The trade was a 6.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Artivion Trading Up 0.4 %

Artivion stock traded up $0.10 during trading on Wednesday, hitting $23.58. The company had a trading volume of 403,807 shares, compared to its average volume of 258,832. The stock has a market cap of $991.37 million, a price-to-earnings ratio of -1,178.85 and a beta of 1.79. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 1-year low of $19.11 and a 1-year high of $32.33. The company’s 50 day simple moving average is $28.93 and its 200-day simple moving average is $27.80.

Artivion (NYSE:AORT) last released its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.51). The firm had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. As a group, analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Artivion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AORT. Quarry LP raised its stake in shares of Artivion by 210.8% in the third quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after acquiring an additional 820 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the period. R Squared Ltd acquired a new stake in Artivion in the 4th quarter valued at about $39,000. Arcadia Investment Management Corp MI purchased a new position in shares of Artivion in the 4th quarter valued at about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Artivion in the 4th quarter valued at about $64,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on AORT shares. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Needham & Company LLC lowered their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Finally, Stifel Nicolaus cut their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.